Avatar Posted by worldpharmanews 63 days ago (http://www.worldpharmanews.com)
Category: Financial | Tags: novo nordisk neose
Novo Nordisk today announced that it has signed an agreement to acquire intellectual property rights from Neose Technologies Inc. related to Neose's proprietary GlycoPEGylation technology. The acquired rights are currently subject to a license from Neose for Novo Nordisk's development of GlycoPEGylated recombinant blood clotting factors FVIIa, FVIII and FIX.
Discuss   Add this link to...  Bury

Comments Who Voted Related Links


News/Blogroll [ alliConnect | BioJobBlog | CNTO411 | Corey Nahman | eDrugSearch | Drug Injury Watch | EyeOnFDA | Forbes ScienceBiz | Healthy Skepticism | JNJ BTW | medGadget | Medical 2.0 | Pharma's Market at CNBC | PharmaFraud | PharmaGossip | Pharmalot | Polish Pharma Market | The Shark Report | World Pharma News | WSJ Health Blog ]
Pharmaceutical Companies [ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

About | Buttons | Contact | Terms and Conditions
Concept and Design by World Pharma News (.com) Project | Powered by Pligg based on PHP/MySQL.
Submit to World Pharma News .net